Search / Trial NCT06231056

Probiotic Supplementation as Prophylactic for Group B β-hemolytic Streptococcus (GBS) Infection

Launched by LIAQUAT UNIVERSITY OF MEDICAL & HEALTH SCIENCES · Jan 20, 2024

Trial Information

Current as of October 04, 2024

Completed

Keywords

Description

There is strong scientific evidence that supports the correlation between bacterial vaginosis (BV), a term used to define a change in the vaginal ecosystem, and spontaneous preterm birth. Antibiotic treatments are recommended to counteract both the presence of S. agalactiae and the onset of BV. The latter, however, are not without risks, as they can in turn cause alterations in the vaginal microbiota and is associated with an increased risk of miscarriage. Recent research have shown that probiotic treatment can help reduc the risk of preterm birth and positivity of Group B β-hemolytic stre...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • * Pregnant women in 24-36 weeks of gestation period
  • * History of recurrent genitourinary and/or intestinal problems
  • Exclusion Criteria:
  • * Presence of neurological condition
  • * History of cardiovascular disease
  • * History of pulmonary disease
  • * History of renal disease
  • * Cancer

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Perugia, , Italy

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0